BioSight
Companies
Definium Therapeutics, Inc. logo

DFTX

NASDAQNEW YORK, NY
Definium Therapeutics, Inc.

Definium develops drug candidates based on psychedelic compounds, including DT120 (a formulation of LSD) and DT402 (R(-)-MDMA), for psychiatric indications such as generalized anxiety disorder. The company is in clinical-stage development, currently running a Phase 3 trial for its lead candidate DT120 as an oral tablet treatment.

Price history not yet available for DFTX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar